Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 11/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17176364 | 0.81 | HTR3A (0.58) | HTR3ALMNAHTR6KCNH2 | |
| SCHEMBL15557431 | 0.81 | HTR3A (0.58) | HTR3AALDH1A1KMT2AHTR6 | |
| SCHEMBL17170615 | 0.80 | HTR3A (0.57) | HTR3AALDH1A1HTR6 | |
| SCHEMBL19970012 | 0.78 | HTR3A (0.55) | HTR3AHTR6KCNH2 | |
| SCHEMBL12748700 | 0.75 | PTGDR2 (0.54) | PTGDR2LMNAHTR6KDM1AMAOA | |
| SCHEMBL28436678 | 0.70 | PTGDR2 (0.48) | PTGDR2LMNARXFP1HTR6KDM1A | |
| SCHEMBL17163414 | 0.70 | HTR3A (1.00) | HTR3A | |
| SCHEMBL17163413 | 0.70 | HTR3A (1.00) | HTR3A | |
| SCHEMBL28436683 | 0.69 | PTGDR2 (0.47) | PTGDR2LMNARXFP1HTR6KDM1A | |
| SCHEMBL28503608 | 0.69 | PTGDR2 (0.44) | PTGDR2LMNAHTR6KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885PTGDR2 230/4885LMNA 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.